Part I: The Lung Cancer Classroom

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Brendon Stiles, MD
Disclosure(s): Arcus Biosciences: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS Foundation: Consultant (Ongoing); Bristol Myers Squib: Consultant (Ongoing); Gala Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing); Medtronic: Consultant (Ongoing); Pfizer: Consultant (Ongoing)

John Mitchell, MD
Disclosure(s): DaVinci Intuitive Surgical: Advisory Board (Ongoing), Consultant (Ongoing)

Presentations

  1. Welcome and Introduction
    John Mitchell, MD
    Disclosure(s): DaVinci Intuitive Surgical: Advisory Board (Ongoing), Consultant (Ongoing)
     
  2. Screening and Incidental Nodule Management
    Douglas E. Wood, MD, FACS, FRCSEd
     
  3. The Surgeon’s Role in Bronchoscopic Biopsy, Staging, and Ablation
    Andrew R. Brownlee, MD
     
  4. Updates on Sublobar Resection—What’s the Evidence?
    Brendon Stiles, MD
    Disclosure(s): Arcus Biosciences: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS Foundation: Consultant (Ongoing); Bristol Myers Squib: Consultant (Ongoing); Gala Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing); Medtronic: Consultant (Ongoing); Pfizer: Consultant (Ongoing)
     
  5. Techniques for Intraoperative Nodule Identification and for Identification of Anatomic Landmarks
    Andrew R. Brownlee, MD
     
  6. Advances in Immunotherapy
    Boris Sepesi, MD
     
  7. Advances in Targeted Therapy
    Michael Lanuti, MD
    Disclosure(s): Medtronic: Consultant (Ongoing)
     
  8. What Did We Learn at the Major Meetings in 2024?
    Jessica S. Donington, MD
    Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)
     
  9. Panel Discussion: Application to the Surgical Clinic
Activity summary
Available credit: 
  • 1.75 ABS Accredited CME
  • 1.75 ABTS Accredited CME
  • 1.75 AMA PRA Category 1 Credit™
Activity opens: 
03/01/2025
Activity expires: 
03/01/2028
Cost:
$0.00
Part of: 
2025 STS Lung Cancer Conference Online: Clinical Trials Meet Clinical Practice
Rating: 
0

Available Credit

  • 1.75 ABS Accredited CME
  • 1.75 ABTS Accredited CME
  • 1.75 AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Brendon Stiles, MD
Disclosure(s): Arcus Biosciences: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS Foundation: Consultant (Ongoing); Bristol Myers Squib: Consultant (Ongoing); Gala Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing); Medtronic: Consultant (Ongoing); Pfizer: Consultant (Ongoing)

John Mitchell, MD
Disclosure(s): DaVinci Intuitive Surgical: Advisory Board (Ongoing), Consultant (Ongoing)

Presentations

  1. Welcome and Introduction
    John Mitchell, MD
    Disclosure(s): DaVinci Intuitive Surgical: Advisory Board (Ongoing), Consultant (Ongoing)
     
  2. Screening and Incidental Nodule Management
    Douglas E. Wood, MD, FACS, FRCSEd
     
  3. The Surgeon’s Role in Bronchoscopic Biopsy, Staging, and Ablation
    Andrew R. Brownlee, MD
     
  4. Updates on Sublobar Resection—What’s the Evidence?
    Brendon Stiles, MD
    Disclosure(s): Arcus Biosciences: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS Foundation: Consultant (Ongoing); Bristol Myers Squib: Consultant (Ongoing); Gala Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing); Medtronic: Consultant (Ongoing); Pfizer: Consultant (Ongoing)
     
  5. Techniques for Intraoperative Nodule Identification and for Identification of Anatomic Landmarks
    Andrew R. Brownlee, MD
     
  6. Advances in Immunotherapy
    Boris Sepesi, MD
     
  7. Advances in Targeted Therapy
    Michael Lanuti, MD
    Disclosure(s): Medtronic: Consultant (Ongoing)
     
  8. What Did We Learn at the Major Meetings in 2024?
    Jessica S. Donington, MD
    Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)
     
  9. Panel Discussion: Application to the Surgical Clinic